#CCTG’s SC30 (RATIONAL) trial has been awarded nearly $1.2 million in funding from CIHR over the next four years. The study investigates treatment options for patients with blood cancers and low antibody levels to prevent serious infections.
https://t.co/18JwN9a8Vn
@SWOG S1925 is still enrolling patients diagnosed with #CLL within the last 18 months with high risk disease. Can time limited early venetoclax + obinutuzumab prolong survival in these patients? We aim to find out. Please consider screening and enrolling your patients!
National Day for Truth and Reconciliation Sacred Fire @queensu
We are asked, what is your next step as we build a future together based on healing and trust?
#EveryChildMatters#NDTR
#CCTG is seeking applicants for a new Senior Investigator (SI) and Chair of Clinical Trials position. The successful candidate will receive five years of direct research support and the opportunity to create a world-class research program. #ClinicalTrials
https://t.co/yXUWmr11Sj
Thanks so much to all those who have already supported our fundraising adventure. Less than 3 weeks to go. All donations go to research/support @MyelomaCanada@KingstonHSC@UHKF
https://t.co/m4e3LT20IL
At a live virtual event on June 10, learn about a gift to the Queen’s Cancer Research Institute that will advance groundbreaking immunotherapy work by panelist Dr. @AnnetteHay1: https://t.co/HsOk4Pq8Uj @QueensCRI
Please enjoy our latest TIME to Talk - Science & Medicine podcast, featuring the delightful @AnnetteHay1🩸. This episode is 'Made in Canada CAR-T therapy: Reprogramming a patient’s cells to kill their cancer’. https://t.co/cshUwyO9as
Myeloma research will inform personalized decisions helping distinguish between people
i) who may benefit from more or earlier treatment and
ii) for whom less is best
@CDNCancerTrials@HiraSMian#woMMen
SMM: Taking the narrow over the wide path https://t.co/jPBsZo5Dxv This is a plea (and not a criticism) to #msmm#myeloma community to heavily invest in genomic, immunogenomic & biomarkers studies to generate better classifiers of risk of progression or redefine SMM as MGUS or MM